RESUMEN
As we all know there is no treatment that can stop or delay the progression of dementia. The treatment we use is only symptomatic. EFNS (European Federation of Neurological Societies) recommendations for dementia prevention by Sorbi et al. (2012) concluded that there is no treatment, no lifestyle, which could have an effect on prevention or delay of onset of different forms of dementia until today. The future studies in prevention must recruit younger people, larger sample, and for longer period. The last 10 years we have run, in collaboration with organizations in different European countries, many projects in order to support patients with neurodegenerative diseases, mainly patients with dementia and their caregivers. The first project was a 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer's disease (AD) in Europe: predictors of discontinuation and switch in the ICTUS (Impact of Cholinergic Treatment USe) study, an FP5 project with 1380 patients. Five studies were published. The second project was DESCRIPA study, an FP5 project to DEvelopment of Screening guidelines and clinical CRIteria for Predementia Alzheimer's disease, with 881 patients with mild cognitive impairment (MCI). LLM (Long Lasting Memories) and VRADA (A virtual reality application for the exercise of dementia and Alzheimer patients) are two projects that include body and cognitive exercise for health for the elderly and patients with mild cognitive impairment. The next is the RECAGE (REspectful Caring for the AGitated Elderly) project (Horizon 2020), a prospective cohort study for coping with behavioral and psychological symptoms of dementia. With six European universities we finished a very interesting FP6 project, the AddNeuroMed one, which gives even now information about the progression of normal elderly MCI and AD patients, in collaboration with other consortia. A very interesting Innovative Medicines Initiative (IMI) project about digital biomarkers was entitled Remote Assessment of Disease and Relapse-Alzheimer's Disease (RADAR project). The main goal of this project was the development and validation of technology-enabled, quantitative and sensitive measures of functional decline in people with early-stage AD. A running project is an Erasmus+ one in the higher education field, "Genetic counseling in European universities: The case of neurodegenerative diseases" (GECONEU project). The target of this study is to develop an online course for university students focusing on genetic counseling, and support people and society to better understand the aims of genetic testing and the usefulness of genetic counseling by involving students in an innovative learning and teaching setting. AD-gaming, BRIDGE, iCONNECT (Intergenerational CONtact between studeNts and people with dEmentia through CreaTive education), E.L.So.M.C.I (English Lessons with the Use of Songs for People with Mild Cognitive Impairment), Games4CoSkills, and De-Sign are all Erasmus+ projects that aim to improve the quality of life of patients with MCI or dementia. Story2remember, Dementia right, ASPAD (Augmentation of the Support of Patients suffering from Alzheimer's Disease and their caregivers), INFOCARE (Supporting Informal Caregivers of People with Dementia), S.IN.CA.L.A (Supporting Informal Carers: A Whole-Family and Life course Approach), and PIA (Peer support workers as an Innovative force in Advocacy in dementia care) are all Erasmus+ projects for training and supporting caregivers of patients with dementia.
Asunto(s)
Enfermedad de Alzheimer , Disfunción Cognitiva , Enfermedades Neurodegenerativas , Humanos , Anciano , Enfermedad de Alzheimer/diagnóstico , Cuidadores/psicología , Calidad de Vida , Estudios Prospectivos , Disfunción Cognitiva/terapia , Disfunción Cognitiva/tratamiento farmacológicoRESUMEN
OBJECTIVE: How do people in contemporary Balkans think about elders and mental capacity, a particular medical and legal concept? SUBJECTS AND METHODS: Different interpretations and applications regarding elders' mental capacity are explored through in-depth semi-structured interviews and field notes of 28 Greeks, 27 Bulgarians and 10 Romanians of varying ages, all living in Northern Greece. This study attempts to shed some light on the perceptions of ageing, mental disease, civil capacities, family and state involvement across three nearby nations. Interpretative phenomenological analysis (IPA), an approach to psychological qualitative research that aims to offer insights into how a given person, in a given context, makes sense of a given phenomenon was used for the first time applied to this topic. RESULTS: Four areas for focus were formed, each relating to the elders and the aging process and presenting the associated themes drawn from the participants' accounts: 1) Discovering the altered-self of the elder, family and society, 2) General experience with old age and capacities in everyday life, 3) Ways of thinking and acting towards old age and capacity issues, and 4) Feelings and comparison thoughts towards old age and capacity issues. Education, occupation, life experience, and especially religious beliefs were all found to be involved in the ways that people from three cultural groups understand the concept of mental capacity and incapacity of elders in their everyday life. A main finding is that the more educated Bulgarians and Romanians tend to speak more easily and to be more positive towards the social construct of aging, while Greeks regardless of their gender, education, religious beliefs, and financial status, tend to consider in their narratives old age as equal to loss of mental capacity, which equals to loss of autonomy and total dependency on others. The process of old age for the group of Greeks begins with retirement which is perceived to reflect withdrawal from social life. This is primarily related to behaviors from individuals and society that result to deprivation of freedom. CONCLUSION: The similarities and differences among these three ethnic groups are discussed, which according to the interviewees discourse reveal peculiar cultural understandings about subordinate themes such as power and its relationship to the self and superordinate themes on emotional control, choice, and individualism.
Asunto(s)
Envejecimiento , Actitud Frente a la Salud , Cognición , Competencia Mental , Actividades Cotidianas , Adulto , Anciano , Anciano de 80 o más Años , Antropología , Peninsula Balcánica , Bulgaria , Comparación Transcultural , Características Culturales , Femenino , Grecia , Educación en Salud , Humanos , Masculino , Pruebas de Estado Mental y Demencia , Persona de Mediana Edad , Investigación Cualitativa , Calidad de Vida , Religión , Rumanía , Estigma SocialRESUMEN
INTRODUCTION: Aß and tau protein have been widely investigated for the diagnosis of dementia entities, most commonly Alzheimer's disease (AD). However, their measurement is an interventional, time-consuming procedure, while it requires specialized personnel, unlike the evaluation of radiological markers, such as Evans index (EI) and Callosal angle (CA). This study aims to investigate the correlation between EI, CA, Aß and total tau in order to outline a basis of diagnostic evaluation for the patient's CSF biomarker profile. METHODS: Sixty-two (62) patients who presented with dementia symptoms participated in this study. Aß and total tau levels in their CSF as well as CA and EI values from their MRIs were measured. Multiple regression was employed to predict Aß and total tau values from EI and CA. From the Durbin-Watson analysis (d1=2.057, d2=1.881) we can assume that there is no first order linear auto-correlation in our multiple linear regression data. RESULTS: The variables statistically significantly predicted both Aß and total tau (F1=8.720, R1=0.484, p1=0.001 and F2=4.110, R2=0.355, p2=0.022). Out of all the variables, it was shown that CA, EI (p<0.05) and CA (p<0.05) added statistically significantly to the prediction of Aß and total tau. CONCLUSION: Collectively, these results support a significant correlation between EI and Aß and CA, Aß and total tau. This highlights the potential role of radiological markers as rough estimates of biomarker levels in everyday clinical practice, assisting to a robust and inexpensive diagnosis.
Asunto(s)
Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/metabolismo , Proteínas tau/metabolismo , Anciano , Anciano de 80 o más Años , Biomarcadores/metabolismo , Femenino , Humanos , Masculino , Análisis de RegresiónRESUMEN
OBJECTIVE: The aim of the present study was to investigate the process of understanding social inferences and metaphors and the pragmatic use of language through emotion recognition and social inference tests in patients diagnosed with Primary Progressive Multiple Sclerosis (PPMS) mainly characterized by neurodegeneration. Additionally, we tried to identify a cerebrospinal fluid (CSF) biomarker correlated with the degree and rate of cognitive decline in progressive MS patients. METHOD: For the purpose of the present study 25 patients, aged 20 up to 55 years, with PPMS were evaluated. All patients were admitted in the First Department of Neurology, AHEPA Hospital of Thessaloniki. The control group was 30 healthy individuals which participated in the study voluntarily. The groups were matched for age, gender, years of education and intelligence. INSTRUMENTS: Social inference was examined with the Awareness of Social Inference Test (TASIT). The TASIT consists of two different parts. The "Tasit Part I: Emotion Evaluation Task (EET - FORM A). The EET is the first part of a broader audiovisual tool designed for the clinical assessment of social perception that is called "The Awareness of Social Inference Test (TASIT)". The second Part of the test TASIT - Social Inference examines the viewer's ability to determine the speaker's meaning and intentions based upon the dialogue, emotional expression, and paralinguistic cues. RESULTS: The findings indicate that patients with PPMS show decline in emotion recognition and social inference abilities, as compared with the control group. More specifically, PPMS patients have problems to understand the affective state of the others mirroring a specific problem in ToM. CONCLUSION: The level of Theory of Mind in the form of sarcasm understanding decreases significantly in MS patients compared with healthy group potentially mirroring impairment in ToM in general. The results indicate that MS group is not resilient to understand metaphoric speech. More specifically, their pathology seems to be able to affect complex ToM abilities.
Asunto(s)
Trastornos del Conocimiento/complicaciones , Cognición , Inteligencia Emocional , Lenguaje , Esclerosis Múltiple/psicología , Conducta Social , Adulto , Biomarcadores/líquido cefalorraquídeo , Estudios de Casos y Controles , Progresión de la Enfermedad , Emociones , Femenino , Humanos , Masculino , Persona de Mediana Edad , Esclerosis Múltiple/líquido cefalorraquídeo , Pruebas Neuropsicológicas , Percepción Social , Adulto JovenRESUMEN
OBJECTIVE: Although Mediterranean diet is connected with longevity and lower rate of many disorders including Alzheimer's disease (AD), the effect of olive oil, which is the principal component of the Mediterranean diet, on fibrinolytic system related to AD and especially on plasminogen activator inhibitor-1 (PAI-1) and a2-antiplasmin in aged participants are not yet examined. This study was performed on 108 aged participants allocated into 5 groups: Mild Cognitive Impairment (MCI) (36) patients subjected to 1-year therapy with extra virgin olive oil (EVOO), MCI without therapy patients (26), MCI without therapy 1-year later patients (11), AD patients (30) and healthy individuals (16). Hypothesis/Purpose: To examine the effect of EVOO therapy on the fibrinolytic factors PAI-1 and a2-antiplasmin, on hallmarks of AD, tau and Aß amyloid fragments and on an oxidative stress biomarker, MDA in the serum of MCI patients aiming to be exploited as a future preventive therapy. RESULTS: Using ELISA method, the levels of both fibrinolytic factors PAI-1 and a2- antiplasmin in the serum of MCI patients were reduced notably in the EVOO treated patients versus the control group and were lower than those of all other groups. For better determination of AD from other pathological conditions the ratio Aß1-42/Aß1-40 was measured in serum of all participants. The more lessened the ratio is, the more cognitive impairment is observed in patients. The MCI group with one-year EVOO therapy displayed a ratio similar to this of healthy individuals. Moreover, patients with EVOO therapy showed decreased tau protein levels in comparison with all the other groups. The levels of the oxidative stress's biomarker, malondialdehyde (MDA) showed a significant decrease in MCI patients subjected to EVOO therapy revealing the involvement of the beneficial antioxidative properties of EVOO in the progression of AD. CONCLUSION: We demonstrated that EVOO therapy may prevent the risk of patients with MCI to progress to AD via decreasing fibrinolytic factors PAI-1 and a2 antiplasmin that reflecting in the diminution of the hallmarks proteins of AD, tau and Aß amyloid as well and in a biomarker of oxidative stress, MDA.
Asunto(s)
Enfermedad de Alzheimer/prevención & control , Disfunción Cognitiva/terapia , Aceite de Oliva/uso terapéutico , Biomarcadores/sangre , Dieta Mediterránea , Progresión de la Enfermedad , Ensayo de Inmunoadsorción Enzimática , Humanos , Malondialdehído/sangre , Estrés Oxidativo , Inhibidor 1 de Activador Plasminogénico/sangre , Riesgo , alfa 2-Antiplasmina/análisis , Proteínas tau/sangreRESUMEN
BACKGROUND: In the field of Alzheimer's disease (AD), the validation of biomarkers for early AD diagnosis and for use as a surrogate outcome in AD clinical trials is of considerable research interest. OBJECTIVE: To characterize the clinical profile and genetic, neuroimaging and neurophysiological biomarkers of prodromal AD in amnestic mild cognitive impairment (aMCI) patients enrolled in the IMI WP5 PharmaCog (also referred to as the European ADNI study). METHODS: A total of 147 aMCI patients were enrolled in 13 European memory clinics. Patients underwent clinical and neuropsychological evaluation, magnetic resonance imaging (MRI), electroencephalography (EEG) and lumbar puncture to assess the levels of amyloid ß peptide 1-42 (Aß42), tau and p-tau, and blood samples were collected. Genetic (APOE), neuroimaging (3T morphometry and diffusion MRI) and EEG (with resting-state and auditory oddball event-related potential (AO-ERP) paradigm) biomarkers were evaluated. RESULTS: Prodromal AD was found in 55 aMCI patients defined by low Aß42 in the cerebrospinal fluid (Aß positive). Compared to the aMCI group with high Aß42 levels (Aß negative), Aß positive patients showed poorer visual (P = 0.001), spatial recognition (P < 0.0005) and working (P = 0.024) memory, as well as a higher frequency of APOE4 (P < 0.0005), lower hippocampal volume (P = 0.04), reduced thickness of the parietal cortex (P < 0.009) and structural connectivity of the corpus callosum (P < 0.05), higher amplitude of delta rhythms at rest (P = 0.03) and lower amplitude of posterior cingulate sources of AO-ERP (P = 0.03). CONCLUSION: These results suggest that, in aMCI patients, prodromal AD is characterized by a distinctive cognitive profile and genetic, neuroimaging and neurophysiological biomarkers. Longitudinal assessment will help to identify the role of these biomarkers in AD progression.
Asunto(s)
Enfermedad de Alzheimer/diagnóstico , Anciano , Enfermedad de Alzheimer/diagnóstico por imagen , Enfermedad de Alzheimer/genética , Péptidos beta-Amiloides/líquido cefalorraquídeo , Apolipoproteínas E/genética , Biomarcadores/líquido cefalorraquídeo , Encéfalo/diagnóstico por imagen , Electroencefalografía , Femenino , Genotipo , Humanos , Imagen por Resonancia Magnética , Masculino , Pruebas Neuropsicológicas , Fragmentos de Péptidos/líquido cefalorraquídeo , Punción Espinal , Proteínas tau/líquido cefalorraquídeoRESUMEN
Memory impairment is the cardinal early feature of Alzheimer's disease, a highly prevalent disorder whose causes remain only partially understood. To identify novel genetic predictors, we used an integrative genomics approach to perform the largest study to date of human memory (n=14 781). Using a genome-wide screen, we discovered a novel association of a polymorphism in the pro-apoptotic gene FASTKD2 (fas-activated serine/threonine kinase domains 2; rs7594645-G) with better memory performance and replicated this finding in independent samples. Consistent with a neuroprotective effect, rs7594645-G carriers exhibited increased hippocampal volume and gray matter density and decreased cerebrospinal fluid levels of apoptotic mediators. The MTOR (mechanistic target of rapamycin) gene and pathways related to endocytosis, cholinergic neurotransmission, epidermal growth factor receptor signaling and immune regulation, among others, also displayed association with memory. These findings nominate FASTKD2 as a target for modulating neurodegeneration and suggest potential mechanisms for therapies to combat memory loss in normal cognitive aging and dementia.
Asunto(s)
Hipocampo/fisiología , Memoria/fisiología , Proteínas Serina-Treonina Quinasas/genética , Proteínas Serina-Treonina Quinasas/metabolismo , Factores de Edad , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/metabolismo , Femenino , Estudios de Asociación Genética , Estudio de Asociación del Genoma Completo , Hipocampo/metabolismo , Hipocampo/fisiopatología , Humanos , Estudios Longitudinales , Masculino , Trastornos de la Memoria/genética , Trastornos de la Memoria/metabolismo , Polimorfismo de Nucleótido Simple , Relación Estructura-ActividadRESUMEN
BACKGROUND: Atrophy in the medial temporal lobe, frontal lobe and posterior cortex can be measured with visual rating scales such as the medial temporal atrophy (MTA), global cortical atrophy - frontal subscale (GCA-F) and posterior atrophy (PA) scales, respectively. However, practical cut-offs are urgently needed, especially now that different presentations of Alzheimer's disease (AD) are included in the revised diagnostic criteria. AIMS: The aim of this study was to generate a list of practical cut-offs for the MTA, GCA-F and PA scales, for both diagnosis of AD and determining prognosis in mild cognitive impairment (MCI), and to evaluate the influence of key demographic and clinical factors on these cut-offs. METHODS: AddNeuroMed and ADNI cohorts were combined giving a total of 1147 participants (322 patients with AD, 480 patients with MCI and 345 control subjects). The MTA, GCA-F and PA scales were applied and a broad range of cut-offs was evaluated. RESULTS: The MTA scale showed better diagnostic and predictive performances than the GCA-F and PA scales. Age, apolipoprotein E (ApoE) ε4 status and age at disease onset influenced all three scales. For the age ranges 45-64, 65-74, 75-84 and 85-94 years, the following cut-offs should be used. MTA: ≥1.5, ≥1.5, ≥2 and ≥2.5; GCA-F, ≥1, ≥1, ≥1 and ≥1; and PA, ≥1, ≥1, ≥1 and ≥1, respectively, with an adjustment for early-onset ApoE ε4 noncarrier AD patients (MTA: ≥2, ≥2, ≥3 and ≥3; and GCA-F: ≥1, ≥1, ≥2 and ≥2, respectively). CONCLUSIONS: If successfully validated in clinical settings, the list of practical cut-offs proposed here might be useful in clinical practice. Their use might also (i) promote research on atrophy subtypes, (ii) increase the understanding of different presentations of AD, (iii) improve diagnosis and prognosis and (iv) aid population selection and enrichment for clinical trials.
Asunto(s)
Enfermedad de Alzheimer/patología , Disfunción Cognitiva/patología , Lóbulo Frontal/patología , Lóbulo Temporal/patología , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/diagnóstico , Atrofia , Corteza Cerebral/patología , Disfunción Cognitiva/diagnóstico , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , PronósticoRESUMEN
BACKGROUND: Visual assessment of medial temporal lobe atrophy (MTA; range 0-4, from no atrophy to increasing atrophy of the choroid fissure, temporal horns and hippocampus) is a sensitive radiological marker of Alzheimer's disease (AD). One of the critical elements for visual MTA assessment is the cut-off score that determines deviation from normality. METHODS: In this study, we assessed the sensitivity and specificity of different MTA cut-off scores to classify control subjects, individuals with mild cognitive impairment (MCI) and AD patients from two large independent cohorts, AddNeuroMed and Alzheimer's Disease Neuroimaging Initiative. Of note, we evaluated the effects of clinical, demographic and genetic variables on the classification performance according to the different cut-offs. RESULTS: A cut-off of ≥1.5 based on the mean MTA scores of both hemispheres showed higher sensitivity in classifying patients with AD (84.5%) and MCI subjects (75.8%) who converted to dementia compared to an age-dependent cut-off. The age-dependent cut-off showed higher specificity or ability to correctly identify control subjects (83.2%) and those with MCI who remained stable (65.5%). Increasing age, early-onset disease and absence of the ApoE ε4 allele had a stronger influence on classifications using the ≥1.5 cut-off. Above 75 years of age, an alternative cut-off of ≥2.0 should be applied to achieve a classification accuracy for both patients with AD and control subjects that is clinically useful. CONCLUSION: Clinical, demographic and genetic variables can influence the classification of MTA cut-off scores, leading to misdiagnosis in some cases. These variables, in addition to the differential sensitivity and specificity of each cut-off, should be carefully considered when performing visual MTA assessment.
Asunto(s)
Enfermedad de Alzheimer , Apolipoproteína E4/análisis , Disfunción Cognitiva , Imagen por Resonancia Magnética , Lóbulo Temporal , Edad de Inicio , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/diagnóstico , Enfermedad de Alzheimer/genética , Atrofia/diagnóstico , Atrofia/epidemiología , Atrofia/metabolismo , Disfunción Cognitiva/diagnóstico , Disfunción Cognitiva/genética , Errores Diagnósticos/prevención & control , Precisión de la Medición Dimensional , Femenino , Variación Genética , Evaluación Geriátrica/métodos , Humanos , Imagen por Resonancia Magnética/métodos , Imagen por Resonancia Magnética/normas , Masculino , Valor Predictivo de las Pruebas , Radiografía , Lóbulo Temporal/diagnóstico por imagen , Lóbulo Temporal/patologíaRESUMEN
Whole-exome sequencing of individuals with mild cognitive impairment, combined with genotype imputation, was used to identify coding variants other than the apolipoprotein E (APOE) ε4 allele associated with rate of hippocampal volume loss using an extreme trait design. Matched unrelated APOE ε3 homozygous male Caucasian participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) were selected at the extremes of the 2-year longitudinal change distribution of hippocampal volume (eight subjects with rapid rates of atrophy and eight with slow/stable rates of atrophy). We identified 57 non-synonymous single nucleotide variants (SNVs) which were found exclusively in at least 4 of 8 subjects in the rapid atrophy group, but not in any of the 8 subjects in the slow atrophy group. Among these SNVs, the variants that accounted for the greatest group difference and were predicted in silico as 'probably damaging' missense variants were rs9610775 (CARD10) and rs1136410 (PARP1). To further investigate and extend the exome findings in a larger sample, we conducted quantitative trait analysis including whole-brain search in the remaining ADNI APOE ε3/ε3 group (N=315). Genetic variation within PARP1 and CARD10 was associated with rate of hippocampal neurodegeneration in APOE ε3/ε3. Meta-analysis across five independent cross sectional cohorts indicated that rs1136410 is also significantly associated with hippocampal volume in APOE ε3/ε3 individuals (N=923). Larger sequencing studies and longitudinal follow-up are needed for confirmation. The combination of next-generation sequencing and quantitative imaging phenotypes holds significant promise for discovery of variants involved in neurodegeneration.
Asunto(s)
Proteínas Adaptadoras de Señalización CARD/genética , Disfunción Cognitiva/genética , Exoma/genética , Predisposición Genética a la Enfermedad/genética , Hipocampo/patología , Poli(ADP-Ribosa) Polimerasas/genética , Enfermedad de Alzheimer/complicaciones , Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/patología , Enfermedad de Alzheimer/psicología , Apolipoproteína E3/genética , Atrofia/patología , Disfunción Cognitiva/complicaciones , Disfunción Cognitiva/patología , Estudios de Cohortes , Estudio de Asociación del Genoma Completo , Humanos , Masculino , Neuroimagen , Poli(ADP-Ribosa) Polimerasa-1 , Polimorfismo de Nucleótido Simple , Población Blanca/genéticaRESUMEN
BACKGROUND: The aim of this study was to evaluate the accuracy of combined structural magnetic resonance imaging (MRI) measures and plasma levels of vitamin E forms, including all eight natural vitamin E congeners (four tocopherols and four tocotrienols) and markers of vitamin E oxidative/nitrosative damage, in differentiating individuals with Alzheimer's disease (AD) and mild cognitive impairment (MCI) from cognitively intact control (CTL) subjects. METHODS: Overall, 81 patients with AD, 86 with MCI and 86 CTL individuals were enrolled from the longitudinal multicentre AddNeuroMed study. MRI and plasma vitamin E data were acquired at baseline. MRI scans were analysed using Freesurfer, an automated segmentation scheme which generates regional volume and cortical thickness measures. Orthogonal partial least squares to latent structures (OPLS), a multivariate data analysis technique, was used to analyse MRI and vitamin E measures in relation to AD and MCI diagnosis. RESULTS: The joint evaluation of MRI and plasma vitamin E measures enhanced the accuracy of differentiating individuals with AD and MCI from CTL subjects: 98.2% (sensitivity 98.8%, specificity 97.7%) for AD versus CTL, and 90.7% (sensitivity 91.8%, specificity 89.5%) for MCI versus CTL. This combination of measures also identified 85% of individuals with MCI who converted to clinical AD at follow-up after 1 year. CONCLUSIONS: Plasma levels of tocopherols and tocotrienols together with automated MRI measures can help to differentiate AD and MCI patients from CTL subjects, and to prospectively predict MCI conversion into AD. Our results suggest the potential role of nutritional biomarkers detected in plasma-tocopherols and tocotrienols-as indirect indicators of AD pathology, and the utility of a multimodality approach.
Asunto(s)
Enfermedad de Alzheimer/clasificación , Cromanos/sangre , Imagen por Resonancia Magnética/métodos , Vitamina E/análogos & derivados , gamma-Tocoferol/sangre , Anciano , Enfermedad de Alzheimer/sangre , Enfermedad de Alzheimer/diagnóstico , Biomarcadores/sangre , Cromatografía Líquida de Alta Presión , Diagnóstico Diferencial , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Pronóstico , Reproducibilidad de los Resultados , Índice de Severidad de la Enfermedad , Tocotrienoles , Vitamina E/sangreRESUMEN
BACKGROUND: Structural magnetic resonance imaging (MRI) is sensitive to neurodegeneration and can be used to estimate the risk of converting to Alzheimer's disease (AD) in individuals with mild cognitive impairment (MCI). Brain changes in AD and prodromal AD involve a pattern of widespread atrophy. The use of multivariate analysis algorithms could enable the development of diagnostic tools based on structural MRI data. In this study, we investigated the possibility of combining multiple MRI features in the form of a severity index. METHODS: We used baseline MRI scans from two large multicentre cohorts (AddNeuroMed and ADNI). On the basis of volumetric and cortical thickness measures at baseline with AD cases and healthy control (CTL) subjects as training sets, we generated an MRI-based severity index using the method of orthogonal projection to latent structures (OPLS). The severity index tends to be close to 1 for AD patients and 0 for CTL subjects. Values above 0.5 indicate a more AD-like pattern. The index was then estimated for subjects with MCI, and the accuracy of classification was investigated. RESULTS: Based on the data at follow-up, 173 subjects converted to AD, of whom 112 (64.7%) were classified as AD-like and 61 (35.3%) as CTL-like. CONCLUSION: We found that joint evaluation of multiple brain regions provided accurate discrimination between progressive and stable MCI, with better performance than hippocampal volume alone, or a limited set of features. A major challenge is still to determine optimal cut-off points for such parameters and to compare their relative reliability.
Asunto(s)
Algoritmos , Enfermedad de Alzheimer/diagnóstico , Encéfalo/patología , Disfunción Cognitiva/diagnóstico , Imagen por Resonancia Magnética/métodos , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/complicaciones , Enfermedad de Alzheimer/fisiopatología , Disfunción Cognitiva/etiología , Disfunción Cognitiva/fisiopatología , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Procesamiento de Imagen Asistido por Computador , Masculino , Persona de Mediana Edad , Pruebas Neuropsicológicas , Reproducibilidad de los Resultados , Índice de Severidad de la EnfermedadRESUMEN
BACKGROUND: People with mild cognitive impairment (MCI) need to prevent the further decline of their cognitive functions, and one way to do so is by learning a foreign language. OBJECTIVE: This study describes the development of a protocol for a novel, non-pharmacological intervention for people with MCI that seeks to prevent or reduce cognitive decline by teaching English through songs. METHODS: The development of this protocol follows a mixed-methodology approach, consisting of three stages: 1) development of the protocol of the intervention, 2) a randomized controlled trial study with two arms over six months that includes an intervention group and a control group, and 3) the evaluation of the protocol by trainers. In the second stage, we recruited a total of 128 people with MCI from the five participating countries of this study (Greece, Spain, Croatia, Slovenia, and Italy). This educational program will assess three main outcomes after 6 months of the English Lessons with the Use of Songs for People with Mild Cognitive Impairment (E.L.So.M.C.I.) workshops. RESULTS: Our primary outcome will hopefully be an improvement in general cognition in the intervention group compared to the control group from baseline to 6 months follow-up. Secondary outcomes include a decrease in participants' anxiety and depression and an improvement in their quality of life. Development of English language skills is the last outcome.
Asunto(s)
Disfunción Cognitiva , Demencia , Humanos , Demencia/psicología , Calidad de Vida , Disfunción Cognitiva/terapia , Disfunción Cognitiva/psicología , Cognición , Ansiedad , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with considerable evidence suggesting an initiation of disease in the entorhinal cortex and hippocampus and spreading thereafter to the rest of the brain. In this study, we combine genetics and imaging data obtained from the Alzheimer's Disease Neuroimaging Initiative and the AddNeuroMed study. To identify genetic susceptibility loci for AD, we conducted a genome-wide study of atrophy in regions associated with neurodegeneration in this condition. We identified one single-nucleotide polymorphism (SNP) with a disease-specific effect associated with entorhinal cortical volume in an intron of the ZNF292 gene (rs1925690; P-value=2.6 × 10(-8); corrected P-value for equivalent number of independent quantitative traits=7.7 × 10(-8)) and an intergenic SNP, flanking the ARPP-21 gene, with an overall effect on entorhinal cortical thickness (rs11129640; P-value=5.6 × 10(-8); corrected P-value=1.7 × 10(-7)). Gene-wide scoring also highlighted PICALM as the most significant gene associated with entorhinal cortical thickness (P-value=6.7 × 10(-6)).
Asunto(s)
Enfermedad de Alzheimer/genética , Encéfalo/patología , Estudio de Asociación del Genoma Completo , Imagen por Resonancia Magnética , Polimorfismo de Nucleótido Simple , Sitios de Carácter Cuantitativo , Enfermedad de Alzheimer/patología , Apolipoproteína E4/genética , Atrofia , Proteínas Portadoras/genética , Progresión de la Enfermedad , Corteza Entorrinal/patología , Femenino , Predisposición Genética a la Enfermedad , Hipocampo/patología , Humanos , Intrones , Desequilibrio de Ligamiento , Masculino , Proteínas de Ensamble de Clatrina Monoméricas/genética , Proteínas del Tejido Nervioso/genética , Tamaño de los Órganos , Fosfoproteínas/genética , Factores de RiesgoRESUMEN
BACKGROUND: Paranoid delusions are a common and difficult-to-manage feature of Alzheimer's disease (AD). We investigated the neuroanatomical correlates of paranoid delusions in a cohort of AD patients, using magnetic resonance imaging (MRI) to measure regional volume and regional cortical thickness. METHODS: 113 participants with probable AD were assessed for severity of disease, cognitive and functional impairment. Presence and type of delusions were assessed using the Neuropsychiatric Inventory (NPI). Structural MRI images were acquired on a 1.5 T scanner, and were analyzed using an automated analysis pipeline. RESULTS: Paranoid delusions were experienced by 23 (20.4%) of the participants. Female participants with paranoid delusions showed reduced cortical thickness in left medial orbitofrontal and left superior temporal regions, independently of cognitive decline. Male participants with delusions did not show any significant differences compared to males without delusions. An exploratory whole brain analysis of non-hypothesized regions showed reduced cortical thickness in the left insula for female participants only. CONCLUSION: Frontotemporal atrophy is associated with paranoid delusions in females with AD. Evidence of sex differences in the neuroanatomical correlates of delusions as well as differences in regional involvement in different types of delusions may be informative in guiding management and treatment of delusions in AD.
Asunto(s)
Enfermedad de Alzheimer/complicaciones , Deluciones/etiología , Lóbulo Frontal/patología , Trastornos Paranoides/etiología , Lóbulo Temporal/patología , Anciano , Enfermedad de Alzheimer/patología , Atrofia , Deluciones/patología , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Neuroimagen , Pruebas Neuropsicológicas , Trastornos Paranoides/patología , Factores SexualesRESUMEN
BACKGROUND: The APOE ε4 allele is a risk factor for Alzheimer's disease (AD). APOE ε4 is common in non-demented subjects with cognitive impairment. In both healthy people and people with AD, its prevalence has a north-south gradient across Europe. In the present study, we investigated whether the relation between the APOE ε4 allele and cognitive impairment varied across Northern, Middle and Southern Europe. We also investigated whether a north-south gradient existed in subjects with subjective cognitive impairment (SCI), amnestic mild cognitive impairment (MCI) and non-amnestic MCI. METHODS: Data from 16 centers across Europe were analyzed. RESULTS: A north-south gradient in APOE ε4 prevalence existed in the total sample (62.7% for APOE ε4 carriers in the northern region, 42.1% in the middle region, and 31.5% in the southern region) and in subjects with SCI and amnestic MCI separately. Only in Middle Europe was the APOE ε4 allele significantly associated with poor performance on tests of delayed recall and learning, as well as with the amnestic subtype of MCI. CONCLUSION: The APOE ε4 allele frequencies in subjects with SCI and amnestic MCI have a north-south gradient. The relation between the APOE ε4 allele and cognition is region dependent.
Asunto(s)
Apolipoproteínas E/genética , Trastornos del Conocimiento/genética , Cognición , Demencia/genética , Trastornos del Conocimiento/epidemiología , Demencia/clasificación , Demencia/epidemiología , Europa (Continente)/epidemiología , Frecuencia de los Genes , Humanos , Valores de Referencia , Topografía MédicaRESUMEN
OBJECTIVES: Apathy has been reported as the most prevalent behavioural symptom experienced in Alzheimer's disease (AD), associated with greater functional decline and caregiver distress. The aim of the current study was to investigate structural correlates of apathy in AD using magnetic resonance imaging (MRI) regional volume and regional cortical thickness measures. METHODS: Semi-structured interviews were conducted with 111 AD patients and their caregivers as part of the European multi-centre study AddNeuroMed. Apathy was measured using the apathy domain of the Neuropsychiatric Inventory (NPI). All AD patients were scanned using a 1.5T MRI scanner and the images analysed using an automated analysis pipeline. RESULTS: We found apathy to be the most prevalent neuropsychiatric symptom occurring in 57% of patients. Apathetic patients had significantly greater cortical thinning in left caudal anterior cingulate cortex (ACC) and left lateral orbitofrontal cortex (OFC), as well as left superior and ventrolateral frontal regions, than those without apathy symptoms. CONCLUSIONS: Apathy is mediated by frontocortical structures but this is specific to the left hemisphere at least for patients in the mild to moderate stages of AD.
Asunto(s)
Enfermedad de Alzheimer/patología , Enfermedad de Alzheimer/psicología , Apatía/fisiología , Corteza Cerebral/patología , Anciano , Anciano de 80 o más Años , Análisis de Varianza , Atrofia/patología , Atrofia/psicología , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Pruebas Neuropsicológicas , Prevalencia , Escalas de Valoración PsiquiátricaRESUMEN
BACKGROUND: The detrimental impact of dementia upon patient health-related quality of life (HRQL) is well established, as is the importance of improving HRQL. However, relatively little is known about the natural history of HRQL in dementia and those factors influencing it. This limited knowledge potentially restricts the evaluation of the efficacy of interventions designed to improve HRQL. One such area concerns the relationship between HRQL and patient insight. It remains unclear what impact, if any, impaired insight has upon a patient's HRQL. The present study aimed to investigate the relationship between insight and HRQL in a sample of patients with Alzheimer's disease (AD) and their carers. METHODS: 256 patients with AD were recruited as part of AddNeuroMed, a multicentre European AD biomarkers study. Of these, 174 completed a quality-of-life measure in addition to a comprehensive battery of clinical and neuropsychological assessments. RESULTS: Insight was found to be differentially related to patient perceptions of HRQL in mild and moderate dementia. Within moderate dementia, impaired insight was associated with better perceived HRQL. Conversely, cognition, but not insight, was associated with impaired HRQL in mild dementia. Insight was not found to be associated with carer perceptions of patient HRQL. CONCLUSION: Impairment of insight is associated with better HRQL in moderate dementia. This finding has implications for interventions which focus on increasing patient awareness and orientation, as impairment of insight appears to have a positive impact upon HRQL.
Asunto(s)
Enfermedad de Alzheimer/psicología , Concienciación , Trastornos del Conocimiento/psicología , Calidad de Vida/psicología , Actividades Cotidianas/psicología , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/diagnóstico , Trastornos de Ansiedad/diagnóstico , Trastornos de Ansiedad/psicología , Cuidadores/psicología , Trastornos del Conocimiento/diagnóstico , Costo de Enfermedad , Trastorno Depresivo/diagnóstico , Trastorno Depresivo/psicología , Femenino , Humanos , Masculino , Trastornos Mentales/diagnóstico , Trastornos Mentales/psicología , Escala del Estado Mental , Persona de Mediana Edad , Pruebas NeuropsicológicasRESUMEN
The prevalence of dementia is reaching epidemic proportions globally, but there remain a number of issues that prevent people with dementia, their families and caregivers, from taking control of their condition. In 2008, Alzheimer's Disease International (ADI) launched a Global Alzheimer's Disease Charter, which comprises six principles that underscore the urgency for a more ambitious approach to diagnosis, treatment and care. This review highlights some of the most important aspects and challenges of dementia diagnosis and treatment. These issues are reviewed in light of the six principles of the recent ADI Charter: promoting dementia awareness and understanding; respecting human rights; recognizing the key role of families and caregivers; providing access to health and social care; stressing the importance of optimal diagnosis and treatment; and preventing dementia through improvements in public health. The authors continue to hope that, one day, a cure for Alzheimer's disease will be found. Meanwhile, healthcare professionals need to unite in rising to the challenge of managing all cases of dementia, using the tools available to us now to work toward improved patient care.
Asunto(s)
Enfermedad de Alzheimer/rehabilitación , Enfermedad de Alzheimer/diagnóstico , Enfermedad de Alzheimer/prevención & control , Cuidadores , Salud de la Familia , Promoción de la Salud , Accesibilidad a los Servicios de Salud , Humanos , Estilo de Vida , Imagen por Resonancia Magnética , Fármacos Neuroprotectores/uso terapéutico , Derechos del Paciente , Guías de Práctica Clínica como Asunto , Rol , Apoyo SocialRESUMEN
BACKGROUND: Clinical subtypes of mild cognitive impairment (MCI) may represent different underlying aetiologies. METHODS: This European, multicentre, memory clinic based study (DESCRIPA) of non-demented subjects investigated whether MCI subtypes have different brain correlates on MRI and whether the relation between subtypes and brain pathology is modified by age. Using visual rating scales, medial temporal lobe atrophy (MTA) (0-4) and white matter hyperintensities (WMH) (0-30) were assessed. RESULTS: Severity of MTA differed between MCI subtypes (p<0.001), increasing from a mean of 0.8 (SD 0.7) in subjective complaints (n = 77) to 1.3 (0.8) in non-amnestic MCI (n = 93), and from 1.4 (0.9) in single domain amnestic MCI (n = 70) to 1.7 (0.9) in multiple domain amnestic MCI (n = 89). The association between MCI subtype and MTA was modified by age and mainly present in subjects >70 years of age. Severity of WMH did not differ between MCI subtypes (p = 0.21). However, the combination of MTA and WMH differed between MCI subtypes (p = 0.02) CONCLUSION: We conclude that MCI subtypes may have different brain substrates, especially in older subjects. Isolated MTA was mainly associated with amnestic MCI subtypes, suggesting AD as the underlying cause. In non-amnestic MCI, the relatively higher prevalence of MTA in combination with WMH may suggest a different pathophysiological origin.